PMID- 34316657
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2590-1125 (Electronic)
IS  - 2590-1125 (Linking)
VI  - 3
DP  - 2020
TI  - Operation of the percutaneous endoscopic gastrostomy-jejunostomy tube without 
      endoscopy in patients with Parkinson's disease on levodopa-carbidopa intestinal 
      gel infusion therapy.
PG  - 100079
LID - 10.1016/j.prdoa.2020.100079 [doi]
LID - 100079
AB  - INTRODUCTION: Tube-related adverse events (AEs) occur frequently in patients with 
      Parkinson's disease (PD) receiving levodopa-carbidopa intestinal gel therapy. 
      Endoscopy has become evasive since the beginning of the coronavirus disease 2019 
      (COVID-19) pandemic. This study aimed to evaluate methods that use the 
      percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tubes without endoscopy. 
      METHODS: We included 19 patients in this study. The contrast agent was injected 
      into the PEG-J tube to clarify the AEs related to the use of the tube. When the 
      kink of the PEG-J tube was found, it was pulled approximately 5-10 cm. When 
      placing or replacing the PEG-J tube, the percutaneous endoscopic gastrostomy 
      (PEG) tube was pushed into the gastrostomy hole to bring its tip closer to the 
      pylorus before a new PEG-J tube was inserted into it. RESULTS: The mean patient 
      age was 63.1 +/- 9.9 years, while the mean duration of PD was 16.7 +/- 6.3 years. 
      Tube-related AEs included PEG-J tube kinks (32 events), connector failures (20 
      events), and PEG-J tube entanglements without/with bezoars (9 events/5 events). 
      All PEG-J tube kinks were resolved by tube manipulation with a fluoroscopic 
      guide. In 66 of 85 events (77.6%), the PEG-J tube was placed or replaced without 
      endoscopy. We believe that the use of the antispasmodic agent just before PEG-J 
      operation reduced this rate. CONCLUSION: Our methods were able to resolve most 
      AEs associated with PEG-J tube use without endoscopy.
CI  - (c) 2020 The Author(s).
FAU - Mukai, Yohei
AU  - Mukai Y
AD  - Department of Neurology, National Center Hospital, Parkinson's Disease & Movement 
      Disorders Center, National Center of Neurology and Psychiatry, Japan.
FAU - Toyoda, Hiroyuki
AU  - Toyoda H
AD  - Department of Surgery, National Center Hospital, National Center of Neurology and 
      Psychiatry, Japan.
FAU - Miyama, Kenji
AU  - Miyama K
AD  - Department of Surgery, National Center Hospital, National Center of Neurology and 
      Psychiatry, Japan.
FAU - Takahashi, Yuji
AU  - Takahashi Y
AD  - Department of Neurology, National Center Hospital, Parkinson's Disease & Movement 
      Disorders Center, National Center of Neurology and Psychiatry, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201117
PL  - England
TA  - Clin Park Relat Disord
JT  - Clinical parkinsonism & related disorders
JID - 101761473
PMC - PMC8298846
OTO - NOTNLM
OT  - Fluoroscopy
OT  - Kink
OT  - Levodopa-carbidopa intestinal gel
OT  - PEG-J tube
OT  - Parkinson's disease
EDAT- 2021/07/29 06:00
MHDA- 2021/07/29 06:01
PMCR- 2020/11/17
CRDT- 2021/07/28 06:36
PHST- 2020/08/08 00:00 [received]
PHST- 2020/10/20 00:00 [revised]
PHST- 2020/11/01 00:00 [accepted]
PHST- 2021/07/28 06:36 [entrez]
PHST- 2021/07/29 06:00 [pubmed]
PHST- 2021/07/29 06:01 [medline]
PHST- 2020/11/17 00:00 [pmc-release]
AID - S2590-1125(20)30047-5 [pii]
AID - 100079 [pii]
AID - 10.1016/j.prdoa.2020.100079 [doi]
PST - epublish
SO  - Clin Park Relat Disord. 2020 Nov 17;3:100079. doi: 10.1016/j.prdoa.2020.100079. 
      eCollection 2020.